[1]王丽丽,石景瑜,张 敏.布地奈德福莫特罗联合噻托溴铵治疗慢阻肺稳定期的临床疗效及药理学分析[J].医学信息,2022,35(23):136-139.[doi:10.3969/j.issn.1006-1959.2022.23.028]
　WANG Li-li,SHI Jing-yu,ZHANG Min.Clinical Efficacy and Pharmacological Analysis of Budesonide Formoterol Combined with Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(23):136-139.[doi:10.3969/j.issn.1006-1959.2022.23.028]
点击复制

布地奈德福莫特罗联合噻托溴铵治疗慢阻肺稳定期的临床疗效及药理学分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年23期
页码:
136-139
栏目:
药物与临床
出版日期:
2022-12-01

文章信息/Info

Title:
Clinical Efficacy and Pharmacological Analysis of Budesonide Formoterol Combined with Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2022）23-0136-04
作者:
王丽丽; 石景瑜; 张 敏
（上饶市广信区人民医院药剂科，江西 上饶 334100）
Author(s):
WANG Li-li; SHI Jing-yu; ZHANG Min
(Department of Pharmacy,Guangxin District People’s Hospital,Shangrao 334100,Jiangxi,China)
关键词:
慢阻肺; 布地奈德福莫特罗; 噻托溴铵; 肺功能; 血气指标
Keywords:
Chronic obstructive pulmonary disease; Budesonide formoterol; Tiotropium bromide; Pulmonary function; Blood gas analysis
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2022.23.028
文献标志码:
A
摘要:
目的 分析布地奈德福莫特罗（BD/FM）联合噻托溴铵（TB）治疗慢阻肺（COPD）稳定期的临床疗效及药理学作用。方法 选取2020年1月-2021年9月于上饶市广信区人民医院就诊的76例COPD稳定期患者，按照随机数字表法分为对照组与观察组，每组38例。对照组应用BD/FM治疗，观察组在对照组基础上联合TB治疗，比较两组临床治疗效果、肺功能指标[第1 s用力呼气量（FEV1）、肺活量（FVC）、第1 s用力呼气量占肺活量百分比（FEV1/FVC）]、血气指标[动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）]、临床症状改善情况[6 min步行实验（6MWT)、COPD患者自我评估测（CAT）、圣乔治呼吸问卷（SGRQ）]、生活质量[健康调查简表（SF-36）评分]以及不良反应发生情况。结果 观察组治疗总有效率高于对照组（P＜0.05）；观察组FVC、FEV1、FEV1/FVC高于对照组（P＜0.05）；观察组PaO2高于对照组，PaCO2低于对照组（P＜0.05）；观察组6MWT结果高于对照组，CAT、SGRQ评分低于对照组（P＜0.05）；观察组SF-36评分高于对照组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 BD/FM联合TB治疗COPD稳定期的效果确切，有利于缓解症状，控制病情，可提升患者肺功能及血气状态，改善患者生活质量，且不增加不良反应。
Abstract:
Objective To analyze the clinical efficacy and pharmacological effects of budesonide formoterol (BD/FM) combined with tiotropium bromide (TB) in the treatment of stable chronic obstructive pulmonary disease (COPD).Methods A total of 76 patients with stable COPD who were treated in Guangxin District People’s Hospital of Shangrao from January 2020 to September 2021 were selected and divided into control group and observation group according to random number table method, with 38 cases in each group. The control group was treated with BD/FM, and the observation group was treated with TB on the basis of the control group. The clinical treatment effect, pulmonary function indexes [forced expiratory volume in the first second (FEV1), vital capacity (FVC), forced expiratory volume in the first second as a percentage of vital capacity (FEV1/FVC)], blood gas indexes [arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2)], improvement of clinical symptoms [6 min walking test (6MWT), COPD patient self-assessment test (CAT), St.George ’s respiratory questionnaire (SGRQ)], quality of life [health survey summary (SF-36) score] and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group (P<0.05). FVC, FEV1 and FEV1/FVC in the observation group were higher than those in the control group (P<0.05). PaO2 in the observation group was higher than that in the control group, and PaCO2 was lower than that in the control group (P<0.05). The results of 6MWT in the observation group were higher than those in the control group, and the scores of CAT and SGRQ were lower than those in the control group (P<0.05). The SF-36 score of the observation group was higher than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion BD/FM combined with TB is effective in the treatment of stable COPD, which is beneficial to relieve symptoms, control the disease, improve the lung function and blood gas status of patients, improve the quality of life of patients, and do not increase adverse reactions.

参考文献/References:

[1]郝文东,王国芳,张彩莲.双水平气道正压通气联合布地奈德福莫特罗对慢性阻塞性肺疾病急性加重合并Ⅱ型呼吸衰竭患者的疗效分析[J].中国卫生检验杂志,2017,27(5):652-654,657.[2]刘艳辉,李洪荣,范永会,等.班布特罗联合TB粉治疗慢性阻塞性肺气肿的临床研究[J].现代药物与临床,2019,34(5):1374-1378.[3]王宁,栗娜,韩巧玲,等.布地奈德福莫特罗联合TB治疗哮喘-慢性阻塞性肺疾病重叠的临床研究[J].中国综合临床,2021,37(1):39-45.[4]石慧,云春梅,魏慧,等.TB联合布地奈德福莫特罗治疗哮喘-慢阻肺重叠综合征临床观察[J].中国药师,2020,23(5):901-904.[5]刘斌,冉献贵,邢青峰,等.TB联合信必可都保治疗对慢阻肺患者肺功能和运动耐量及不良反应的影响[J].河北医学,2019,25(7):1108-1112.[6]中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.[7]李方方,张高峰.TB+信必可都保治疗慢阻肺的有效性及对患者运动耐力的影响[J].贵州医药,2021,45(9):1396-1397.[8]方佳,肖翔,李瑞金,等.TB联合福莫特罗/布地奈德治疗哮喘-慢性阻塞性肺疾病重叠综合征的疗效分析[J].临床内科杂志,2018,35(3):203-204.[9]刘颖,薄晓霞,张亚娟.布地奈德福莫特罗、TB、家庭无创正压通气对慢性阻塞性肺疾病患者影响的研究[J].临床肺科杂志,2018,23(8):1394-1397.[10]张祥乐,何美燕,邓玲,等.布地奈德福莫特罗吸入辅治哮喘伴慢性阻塞性肺疾病对肺功能及炎性因子的影响[J].疑难病杂志,2018,17(1):5-9.[11]姜锋,郑洪飞,柳雅军,等.TB粉吸入剂联合茶碱缓释片治疗稳定期慢性阻塞性肺疾病的临床研究[J].中国临床药理学杂志,2017,33(22):2233-2235,2238.[12]蔡波.TB吸入剂治疗稳定期老年慢阻肺患者的疗效分析[J].徐州医学院学报,2016,36(9):595-598.[13]王宏举,顾继红,张凡.不同剂量布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病稳定期患者的临床疗效比较[J].实用心脑肺血管病杂志,2016,24(9):158-160.[14]张琼.布地奈德福莫特罗粉吸入剂在稳定期慢性阻塞性肺疾病的临床观察[J].中国药物与临床,2016,16(5):735-737.[15]李新鹏.布地奈德福莫特罗联合呼吸康复训练治疗慢性阻塞性肺疾病的疗效观察[J].中国临床医生杂志,2017,45(5):41-43.[16]区健民,祝小林,张强,等.布地奈德福莫特罗粉吸入剂与氨茶碱片治疗缓解期慢性阻塞性肺疾病的疗效对比[J].广西医科大学学报,2017,34(4):575-578.[17]李研,佟飞,米香.布地奈德福莫特罗粉吸入剂联合TB粉吸入剂治疗ACOS的疗效及其对患者血清hs-CRP、EOS的影响[J].海南医学,2017,28(18):2997-3000.[18]余霓雯,王玉婷.TB联合布地奈德福莫特罗对慢性阻塞性肺疾病的疗效及血清TGF-β、MMP-9、TIMP-1水平的影响[J].东南国防医药,2017,19(2):183-186.[19]庄英鸿,尚东,巫瑞.TB联合布地奈德福莫特罗吸入剂治疗稳定期慢性阻塞性肺疾病的临床疗效研究[J].药物评价研究,2017,40(11):1626-1630.[20]蓝杨,韩序,王媛媛,等.TB联合“六字诀”锻炼对慢阻肺稳定期患者生活质量及肺功能的影响[J].世界中西医结合杂志,2016,11(10):1369-1371,1395.[21]许柳柳,朱洁晨,卞宏,等.布地奈德福莫特罗联合TB吸入剂治疗慢阻肺疗效及对CRP、SaO2、PH水平影响[J].现代生物医学进展,2020,20(22):4369-4372.[22]薛佩妮,冯敏娟,王惠琴.TB粉联合糖皮质激素治疗慢性阻塞性肺疾病疗效及对患者生活质量评分的影响[J].陕西医学杂志,2020,49(2):216-219.

相似文献/References:

[1]黄朝宗.无创呼吸机对慢性阻塞性肺疾病急性加重患者治疗效果的影响[J].医学信息,2018,31(01):112.[doi:10.3969/j.issn.1006-1959.2018.01.042]
　HUANG Chao-zong.Effect of Noninvasive Ventilator on the Treatment of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(23):112.[doi:10.3969/j.issn.1006-1959.2018.01.042]
[2]温 蕾.复方异丙托溴铵常温雾化与加温雾化治疗 慢阻肺的护理效果分析[J].医学信息,2018,31(06):170.[doi:10.3969/j.issn.1006-1959.2018.06.061]
　WEN Lei.Analysis of Nursing Effect of Compound Ipratropium Bromide Nebulization at Room Temperature and Heating Atomization in Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(23):170.[doi:10.3969/j.issn.1006-1959.2018.06.061]
[3]王春艳,平玉卓,赵秀芹,等.协同护理干预对慢阻肺患者预后及自我护理能力的影响观察[J].医学信息,2018,31(13):181.[doi:10.3969/j.issn.1006-1959.2018.13.057]
　WANG Chun-yan,PING Yu-zhuo,ZHAO Xiu-qin,et al.Effect of Cooperative Nursing Intervention on Prognosis and Self-care Ability of Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(23):181.[doi:10.3969/j.issn.1006-1959.2018.13.057]
[4]鲁 婧,杜 君.肺心病左室舒张功能障碍发病机制的研究进展[J].医学信息,2019,32(04):54.[doi:10.3969/j.issn.1006-1959.2019.04.019]
　LU Jing,DU Jun.Advances in the Pathogenesis of Left Ventricular Diastolic Dysfunction in Pulmonary Heart Disease[J].Journal of Medical Information,2019,32(23):54.[doi:10.3969/j.issn.1006-1959.2019.04.019]
[5]周 笳,董丽霞.阿替普酶联合华法林治疗慢阻肺合并肺栓塞的有效性分析[J].医学信息,2019,32(05):146.[doi:10.3969/j.issn.1006-1959.2019.05.046]
　ZHOU Jia,DONG Li-xia.Efficacy Analysis of Alteplase Combined with Warfarin in the Treatment of Chronic Obstructive Pulmonary Disease with Pulmonary Embolism[J].Journal of Medical Information,2019,32(23):146.[doi:10.3969/j.issn.1006-1959.2019.05.046]
[6]刘伟娜.CD64感染指数、BODE指数与降钙素原在慢阻肺患者中的水平变化[J].医学信息,2019,32(06):125.[doi:10.3969/j.issn.1006-1959.2019.06.039]
　LIU Wei-na.Changes of CD64 Infection Index,BODE Index and Procalcitonin Levels in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2019,32(23):125.[doi:10.3969/j.issn.1006-1959.2019.06.039]
[7]钟红燕.盐酸氨溴索治疗慢阻肺合并肺部感染的临床效果[J].医学信息,2019,32(12):154.[doi:10.3969/j.issn.1006-1959.2019.12.051]
　ZHONG Hong-yan.Clinical Effect of Ambroxol Hydrochloride in the Treatment of Chronic Obstructive Pulmonary Disease with Pulmonary Infection[J].Journal of Medical Information,2019,32(23):154.[doi:10.3969/j.issn.1006-1959.2019.12.051]
[8]蔡 懿.医教协同专科治疗对慢阻肺患者肺功能和疗效的影响[J].医学信息,2023,36(19):110.[doi:10.3969/j.issn.1006-1959.2023.19.023]
　CAI Yi.Effect of Medical Education Combined with Specialized Treatment on Pulmonary Function and Efficacy in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2023,36(23):110.[doi:10.3969/j.issn.1006-1959.2023.19.023]
[9]郑 新,张 颖.慢阻肺患者PSQI评分与NLR、PLR、CRP水平及急性加重频率的相关性[J].医学信息,2020,33(12):103.[doi:10.3969/j.issn.1006-1959.2020.12.031]
　ZHENG Xin,ZHANG Ying.Correlation of PSQI Score with NLR,PLR,CRP Level and Frequency of Acute Exacerbation in COPD Patients[J].Journal of Medical Information,2020,33(23):103.[doi:10.3969/j.issn.1006-1959.2020.12.031]
[10]孙 茜.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢性阻塞性肺疾病的疗效[J].医学信息,2022,35(20):60.[doi:10.3969/j.issn.1006-1959.2022.20.014]
　SUN Qian.Efficacy of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(23):60.[doi:10.3969/j.issn.1006-1959.2022.20.014]
[11]王浩凌,李冬琼,吴 旭,等.布地奈德联合噻托溴铵治疗慢阻肺的效果及对CRP、SaO2、pH水平的影响[J].医学信息,2023,36(06):143.[doi:10.3969/j.issn.1006-1959.2023.06.031]
　WANG Hao-ling,LI Dong-qiong,WU Xu,et al.Effect of Budesonide Combined with Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP,SaO2 and pH Levels[J].Journal of Medical Information,2023,36(23):143.[doi:10.3969/j.issn.1006-1959.2023.06.031]
[12]孙 茜,柴明思,齐秀芳.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺的疗效及对CRP、SaO2、pH水平影响[J].医学信息,2023,36(10):150.[doi:10.3969/j.issn.1006-1959.2023.10.033]
　SUN Qian,CHAI Ming-si,QI Xiu-fang.Efficacy of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP, SaO2 and pH Levels[J].Journal of Medical Information,2023,36(23):150.[doi:10.3969/j.issn.1006-1959.2023.10.033]

更新日期/Last Update: 1900-01-01